Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

ARTV - Artiva Biotherapeutics, Inc. So'nggi... | Finranks

Home

ARTV

A

Artiva Biotherapeutics, Inc. (ARTV)

NGM – Real vaqt narxi. Valyuta: USD

5.01

-0.15 (-2.91%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

5.11

+0.10 (2.05%)

Bozordan keyin: Mar 27, 2026, 5:49 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA.

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation.

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis.

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL). The following abstracts will be presented as poster presentations at the 2026 Tandem Meetings: Poster ID: 440 AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases Poster Session: Health Services and Barriers to Access Date / Time: Thursday, February 5, 2026, at 6:30 pm MST Author: Nicholas Veomett, Ph.D.

Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored

Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored

Artiva Biotherapeutics is working on NK cell-based immunotherapy to treat autoimmune disease. Their lead project is an unmodified, preserved NK product that seeks to address challenges posed for CAR T-cell therapies. Early trial data in B-cell lymphoma suggests activity, and ARTV is guiding a data readout in the near term for autoimmune disease.

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were treated in community rheumatology trial sites with no specialized oncology oversight, demonstrating the feasibility of administering this regimen outside the hospital setting No cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) Consistent and complete B-cell depletion was observed in all patients with autoimmune disease treated with AlloNK + mAb by Day 13 of treatment, consistent with the experience for AlloNK + mAb in B-cell driven lymphoma Artiva remains on track to share initial clinical response data and conduct U.S. Food and Drug Administration (FDA) regulatory interactions to align on pivotal trial design for AlloNK in refractory rheumatoid arthritis (RA) in the first half of 2026 Management will host a webcast today at 8:00 a.m. ET SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced positive initial safety and translational data from ongoing clinical trials of AlloNK® (also known as AB-101) in combination with rituximab or obinutuzumab for the treatment of autoimmune disease.

Videolar

No Data

There is no data to display

Press-relizlar

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

25.02.2026

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA.

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation.

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis.